toripalimab

Latest news

Tag

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly en

Jul 20, 2026Sign in to read

news

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man

Jan 6, 2026

Clinical Updates

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Aug 2, 2025